PolyPeptide publishes invitation to the annual General Meeting 2025

Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug.
At PolyPeptide Group AG’s (the “Company”) fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug (the “AGM 2025”), five current members of the Board of Directors will stand for re-election. Beat In-Albon has decided not to stand for re-election as a member of the Board of Directors. The Board of Directors thanks Mr. In-Albon for his dedicated service and valuable contributions. Peter Wilden is proposed for re-election as Chair of the Board of Directors, and Philippe Weber and Peter Wilden as members of the Remuneration and Nomination Committee. As announced on 11 March 2025, the Board of Directors further proposes Jo LeCouilliard for election as new independent member of the Board of Directors, and upon election it is expected that Ms. LeCouilliard will join the Audit and Risk Committee.
The Board of Directors further proposes to the AGM 2025 the introduction of a capital band in a new art. 3a of the Company’s Articles of Association and the introduction of a conditional share capital for financing purposes and finance instruments in a new art. 3c of the Company’s Articles of Association. The capital band shall provide the Board of Directors with the flexibility to increase the Company’s share capital within a predefined range, thereby enhancing the Company’s financial and strategic agility. The conditional share capital shall increase the Company’s financing and refinancing flexibility.
Further proposals include, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders will also be asked to approve the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on non-financial matters, in each case, for the financial year 2024 as well as the Remuneration Report 2024 in separate consultative vote.
The invitation to the AGM 2025 with the detailed proposals and explanations can be found here